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Abstract
In recent years a new very promising drug was introduced for the treatment of chronic heart failure. This drug, 
sacubitril/valsartan, prevents the clinical progression of surviving patients with heart failure more effectively than 
enalapril and it reduces the need for hospitalization by more than 20%. At the same time it has been shown that it 
reduces blood pressure particularly in patients with essential hypertension. This drug is an inhibitor of neprilysin, 
an enzyme that degrades natriuretic factors. Natriuretic factors (ANP, BNP, CNP) increase diuresis and natriuresis, 
reduce the activity of the sympathetic system, relax the blood vessels and inhibit fibrosis. Several studies have shown 
that sacubitril/valsartan therapy more significantly reduces blood pressure in patients with salt-sensitive or refractory 
to treatment hypertension than is observed with valsartan or amlodipine. Furthermore, beneficial effects of this drug 
on central blood pressure and renal function have been demonstrated in patients with chronic renal failure. More 
rarely than enalapril it leads to hyperkalaemia in patients treated simultaneously with mineralocorticoid receptor in-
hibitors. Sacubitril/valsartan is the first representative of a new class of drugs that inhibit neprilysin, which probably 
in the future will be frequently used in hypertension.
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In the last 30 years, no new class of antihyper-
tensive drugs has been included into the treatment 
of hypertension. For many years, the guidelines of 
Societies of Hypertension have been invariably list-
ing the same classes as the drugs of first choice. Al-
though new formulations characterized by fewer side 
effects (e.g. lercanidipin or zofenopril) did appear 
on the Polish pharmaceutical market, they belong 
to the already known calcium antagonists and ACE 
inhibitors. Progress in the treatment of hypertension 
involves skilful combination of the already known 
antihypertensive drugs of different classes, which in-
creases the effectiveness of the treatment and reduces 
the occurrence of side effects. 
Recently, a new drug, effective in the treatment of 
heart failure has been introduced into cardiology [1]. 
The drug is called sacubitril/valsartan — (Entresto 
Novartis, already available in Poland). It deserves 
special attention also from hypertensiologists, as it 
significantly reduces blood pressure. Neprilysin in-
hibitor included in the drug inhibits the degradation 
of the biologically active natriuretic factors that in-
crease diuresis and blood vessel relaxation. Nepri-
lysin (also called neutral endopeptidase — NEP) 
is a membrane-bound metalloendopeptidase and is 
widely distribute d in the body tissues, especially in 
the brush border of the proximal renal tubule [2]. 
The primary function of this compound is based on 
enzymatic degradation of natriuretic factors, as well 
as endothelin-1, substance P, gastrin and beta-amy-
loid protein [3]. Currently, 3 natriuretic peptides are 
known, i.e. atrial natriuretic factor (ANP), brain na-
triuretic factor (BNP) and C-type natriuretic factor 
(CNP) [4]. Natriuretic factor type A and type B is 
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synthesized primarily in cardiomyocytes in response 
to myocardial tension. C-type natriuretic factor is 
synthesized primarily in endothelial cells. B-type is 
also synthesized by cardiac fibroblasts and prevents 
myocardial fibrosis [2]. All of these natriuretic fac-
tors are active via a second messenger, i.e. cyclic 
guanosine monophosphate-3-5 (cGMP), potentiate 
diuresis and natriuresis, dilate blood vessels and, in 
addition, reduce the tone of the sympathetic system 
and suppresses fibrosis [5, 6]. Recent studies indi-
cate that natriuretic factors influence the growth and 
proliferation of endothelial cells by reducing the im-
pact of such atherogenic factors as cell proliferation, 
apoptosis, angiogenesis and inflammation. More and 
more data support the fact that hypertension and 
heart failure are accompanied by a shortage of natri-
uretic factors [2]. High level of BNP in blood serum 
in response to fluid overload is insufficient because 
of impaired activity of these compounds in heart 
failure. Studies indicate that the hypertension reveals 
impaired process of BNP synthesis from precursor 
pro-BNP, leading to reduced biological activity of 
this hormone [2]. 
The biologically active ANP dilates the blood ves-
sels supplying blood to the renal glomeruli (afferent 
vessels) and narrows efferent vessels, which increases 
the glomerular filtration and diuresis [7]. In addi-
tion, this compound elicits relaxation of mesangial 
cells and increases the filtration surface. The animals 
lacking the gene responsible for the pro-ANP synthe-
sis develop sodium sensitive hypertension and have 
a tendency for heart hypertrophy, stroke and kidney 
damage [8]. The reintroduction of this gene reduces 
the blood pressure and prevents organ damage [9]. 
The concentration of neprilysin (also called neu-
tral endopeptidase) significantly correlates with the 
severity of heart failure and mortality [10]. For this 
reason, attempts have been made to synthesize nepri-
lysin inhibitor and to use it as a medicine reduc-
ing the risk of these complications. Candoxatrilat 
was one of the first of these compounds. This drug 
increased levels of natriuretic factors (ANP, BNP 
CNP) and diuresis, but it did not lower blood pres-
sure probably through the simultaneous increase in 
endothelin and angiotensin-II [11]. Another drug, 
omapatrilat, is a combination of neprilysin and ACE 
inhibitor. This drug reduced cardiovascular mortality 
in the IMPRESS study, but has not been approved 
for routine use by the US Food and Drug Admin-
istration because of the high risk of developing an-
gioedema, which were observed in the OCTAVE 
and OVERTURE studies [12]. Only a combination 
of neprilysin inhibitor with valsartan significantly 
reduced side effects, at the same time showing high 
efficacy in patients with chronic heart failure and, as 
shown in recent studies, also in hypertension.
First, in experimental rats of SHR breed (sponta-
neously developing sodium-sensitive hypertension), 
sacubitril/valsartan caused a greater decrease in blood 
pressure compared to valsartan [13]. It also increased 
renal excretion of sodium and inhibited the activity 
of the sympathetic nervous system. Furthermore, 
a substantial reduction of adverse remodelling of the 
heart and reduction of inflammation and improve-
ment of endothelial function in comparison with 
valsartan were observed [13]. Mura et al. demon-
strated that sacubitril not only greatly increases the 
excretion of ANP and BNP but also decreases the 
aldosterone synthesis in tissue culture of the adrenal 
cortex cells [14]. 
Sacubitril, neprilysin inhibitor is a prodrug 
marked as AHU377. After oral intake, the drug is 
rapidly metabolized to the active neprilysin inhib-
itor marked as LBQ657 [15]. The maximum con-
centration of the latter compound is observed after 
2 hours and the half-life is 11.5 hours. Maximum con-
centrations of valsartan in serum and its half-life are 
very similar — 1.5 hours and 10 hours, respectively. 
These data indicate that the best dosage of LCZ696 
is its administration two times a day. After admin-
istration of the sacubitril/valsartan we can observe 
the increase in the blood concentration of the cyclic 
guanosine monophosphate and renin and angioten-
sin II in response to administration of valsartan [15]. 
Gan et al. evaluated the effect of age and gender on 
the pharmacokinetics of the drug administered at 
a dose of 400 mg/day in 19 healthy men and 17 
women. Eighteen persons were aged 18–45 years 
and 18 respondents were aged 65 and older. The half-
life of the drug was 30% longer in the elderly; the 
maximum concentration of drug in the blood was 
similar in both groups. The maximum concentration 
of valsartan was 30% higher in the elderly. All tested 
pharmacological parameters were the same in males 
and in females. The authors conclude that the gender 
and age of the respondents do not play a significant 
role in the dosage of the drug [16]. 
The PARADIGM-HF study involving 8000 pa-
tients with heart failure revealed that the therapy 
with sacubitril/valsartan resulted not only in statis-
tically significant improvement of heart failure and 
a reduction in mortality, but also had a slight de-
crease in blood pressure amounting to an average 
of 9.3/4.9 mmHg after 12 weeks of therapy [1]. In 
contrast, patients treated only with valsartan had 
a significantly lower level (p < 0.05) decrease in 
blood pressure (2.9/2.1 mmHg). After 36 weeks of 
treatment, analogous decreases were 7.5/5.1 mmHg 
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and 1.5/0.3 mmHg. It was noted that in patients 
with normal blood pressure sacubitril/valsartan did 
not considerably lower blood pressure, and pressure 
drops were the highest with the highest initial pres-
sures. The multicentre PARAMETER study involv-
ing 454 patients aged over 60 years with hyperten-
sion and pulse pressure above 60 mmHg compared 
the effects of sacubitril/valsartan 400 mg/day with 
olmesartan 80 mg/day on central aortic pressure [17]. 
After 12 weeks of this therapy it has been shown that 
sacubitril/valsartan more significantly reduced sys-
tolic central pressure (by 12.6 mmHg) compared to 
olmesartan that reduced systolic central pressure only 
by 8.9 mmHg (p < 0.01). Systolic blood pressure 
measured on the shoulders dropped by 13.7 and 9.9 
mmHg, respectively. There was also more significant 
reduction of pulse pressure after the administration 
of sacubitril/valsartan [17].
Wang et al. compared the diuresis and natriuresis 
under sacubitril/valsartan and valsartan in 72 pa-
tients with sodium sensitive hypertension [18]. This 
randomized, double-blind, cross-over study diag-
nosed sodium sensitive hypertension, if the mean 
arterial pressure (MAP) increased at least by 10% 
after switching from diet containing 50 mmol of 
sodium per day to 320 mmol of sodium per day 
(both diets used for seven days). Patients were treat-
ed for 28 days with sacubitril/valsartan at a dose of 
400 mg/day or valsartan 320 mg/day. Diuresis was 
examined on the first day after 6 and 24 hours after 
administration of the study drug, and then on 28th 
day of therapy, using the same procedure. On the 
first day, the two measurements showed that sacubi-
tril/valsartan caused higher increase in diuresis and 
natriuresis than valsartan. However, after 28 days, 
the diuresis and natriuresis were similar in sacubitril/ 
/valsartan and valsartan groups. These data show that 
the investigational drug only initially increases the 
renal excretion of sodium and the effect weakens and 
disappears after a month of treatment [18]. 
Japanese researchers, Kario et al., administered 
sacubitril to 32 patients with severe hypertension, 
so far untreated or not taking medication for four 
weeks [19]. The inclusion criterion was systolic blood 
pressure higher than 180 m Hg or diastolic blood 
pressure higher than 110 mmHg. Sacubitril start-
ing dose was 200 mg/day. If blood pressure was 
not reduced below 160/100 mmHg, the dose was 
increased to 400 mg/day. If the blood pressure after 
4 weeks did not decrease below 140/90 mmHg, oth-
er antihypertensive agents were included, with the 
exception of ACE inhibitors and sartans. The mean 
baseline systolic pressure was 173.4 mmHg and di-
astolic pressure was 112.4 mmHg. After a week of 
treatment, the systolic blood pressure decreased by 
18.7 and diastolic blood pressure by 10.3 mmHg. 
After 4 weeks of therapy with sacubitril it was 150.3 
and diastolic was 98.5 mmHg. After 8 weeks of 
combination therapy, blood pressure values were re-
spectively 138.1/90.3 mmHg. The drug was well 
tolerated, with only some patients reporting rhinitis 
and pharyngitis [19].
In a large group of 389 patients with hypertension, 
Kario et al. evaluated the effect of different doses of 
sacubitril and placebo on blood pressure measured 
by ABPM. Each dose of sacubitril, 100 mg, 200 mg 
and 400 mg/day, more significantly decreased the 
measurement of clinical blood pressure compared 
to placebo (p < 0.0001). ABPM also revealed blood 
pressure drop, both during the day and the night. 
There were no serious side effects, particularly no 
patient reported angioedema [20]. 
The largest group of hypertensive patients (n = 
1328) treated with sacubitril/valsartan was analysed 
by Ruilope et al. [21]. These authors compared the 
effect of this drug in a dose of 100, 200 and 400 mg/ 
/day, with the effects of valsartan 80, 160, and 320 
mg/day and with placebo on diastolic pressure. After 
8 weeks of the study, the drug slightly but statistically 
significantly decreased diastolic blood pressure more 
than valsartan. Three patients experienced severe side 
effects; however, they turned out to be not related to 
the tested drug [21].
The longest, lasting 52 weeks, study on the effica-
cy and safety of LCZ696 was conducted on a group 
of 341 patients with hypertension by Supasyndh 
et al. [22]. Patients whose blood pressure was not 
normalized after a dose of 400 mg two times a day 
of sacubitril/valsartan also received amlodipine and 
Figure 1. Mechanism of action of sacubitril/walsartan
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hydrochlorothiazide. After 52 weeks, blood pres-
sure was reduced by 24.7/16.2 mmHg. Seventy-five 
percent of patients had a reduction of pressure be-
low 140/90 mmHg; 18.2% of patients experienced 
symptoms of rhinitis and nasopharyngitis, 8.8% of 
patients complained of dizziness. One patient had 
angioedema [22]. 
Already quoted Wang compared in another study 
the efficacy and safety of coadministration of sacubi-
tril/valsartan with amlodipine 5 mg and amlodipine 
5 mg alone in patients with hypertension in whom 
the dose of amlodipine alone did not prove to be an 
effective drug [23]. After eight weeks of this therapy, 
in 165 patients on combined treatment with sacubi-
tril/valsartan and amlodipine 24-hour blood pressure 
decreased by 13 mmHg and in 160 consecutive pa-
tients on amlodipine alone blood pressure decreased 
by 0.8 mmHg. Pulse pressure decreased by 5.8 vs 
0.6 mmHg. Adverse reactions occurred with equal 
frequency in both treatment groups.
Hypertension often accompanies chronic kidney 
disease (CKD). According to Konta et al., 58% of 
patients with chronic renal disease have hypertension 
and in individuals with normal renal function the 
prevalence of hypertension was 42% [2]. Further-
more, in CKD patients, hypertension is often resis-
tant to antihypertensive therapy and in only 22% 
it is possible to achieve a normalization of blood 
pressure, in contrast to the patients without kidney 
function impairment in whom the correct blood 
pressure is achieved in 44% [24]. Ito at al. assessed 
the efficacy and safety of sacubitril/valsartan in pa-
tients with hypertension and renal failure [25]. The 
initial blood pressure of the patients was 151.6/86.9 
mmHg, GFR was lower than 60 mL/min and in 
21% of patients it ranged from15 to 30 mL/min. 
After 8 weeks of treatment with an initial dose of 
200 and 400 mg of the target dose of sacubitril/val-
sartan, blood pressure decreased by 20.5/8.3 mmHg. 
Blood pressure drop was the highest during the first 
two weeks, slightly lower in the subsequent 14 days, 
and then the values of blood pressure did not change 
until the end of the study. The geometric mean of 
urinary protein decreased by 15.1%. The proportion 
of patients with well-controlled blood pressure also 
increased [25]. No significant changes in levels of 
creatinine, urea and potassium in the blood serum 
were observed. The authors of this study speculated 
that the beneficial effect in patients with severe renal 
failure is due to the increase of blood flow in the re-
nal medulla. There were also no serious side effects; 
only one patient discontinued the drug because of 
headaches. None of the patients complained about 
the dizziness and angioedema. 
The aim of the study of Voors’ et al. was to assess 
the impact of sacubitril/valsartan on renal parameters 
in patients with heart failure with preserved systolic 
function [26]. The study included 301 patients who 
were randomly assigned to therapy with sacubitril/ 
/valsartan or valsartan alone. All patients were sub-
jected to the evaluation of creatinine and cystatin C 
levels in serum, glomerular filtration rate and urinary 
albumin excretion at baseline, after 12 and after 36 
weeks of treatment. Significant deterioration in renal 
function was defined as an increase in the concentra-
tion of serum creatinine of 0.3 mg% and/or > 25%. 
At baseline, the glomerular filtration rate (GFR) was 
65.4 ± 20.4 mL/min. The decrease in GFR was low-
er in patients receiving sacubitril/valsartan than in 
those on valsartan (1.5 v 5.2 mL/min, respectively; 
p = 0.002). Significant deterioration in renal func-
tion occurred in 12% of patients in sacubitril/valsar-
tan group and in 18% of patients in valsartan group. 
After 36 weeks of therapy, the geometric mean of uri-
nary protein excretion increased from 2.4 to 2.9 mg/ 
/mmol in sacubitril group and did not change in pa-
tients treated with valsartan (from 2.1 to 2 mg/mmol 
of creatinine; p = 0.016). Thus, renal parameters were 
much better after treatment with sacubitril compared 
with valsartan, with the exception of increased ex-
cretion of protein in the urine. This last parameter 
is considered an important predictor; an increase in 
urinary protein excretion is usually an expression of 
deterioration of renal function [26]. However, some 
authors believe that increased proteinuria is an ex-
pression of increased permeability of the glomerulus 
under the influence of natriuretic factors and is not 
related to a deterioration of renal function [27–29]. 
Meta-analysis performed by Bodey et al. showed that 
omapatrilat (IMPRES, OVERTURE) and sacubitril/ 
/valsartan (PARADIGM-HF and PARAMOUNT) 
reduce by 32% the risk of kidney damage compared 
with a convertase inhibitor or a sartan [30]. The UK 
HARP III trial was planned in order to explain the 
impact of neprilysin inhibitor on kidney function in 
patients with renal failure [31]. 
Moreover, sacubitril/valsartan is characterized by 
favourable effects on insulin resistance. Jordan et 
al. administered sacubitril/valsartan 400 mg/day or 
amlodipine 10 mg/day for 8 weeks in patients with 
hypertension and obesity [32]. Insulin sensitivity 
was assessed by euglycaemic clamp. The therapy with 
sacubitril/valsartan significantly increased insulin 
sensitivity, while treatment with amlodipine had no 
effect on its level [32]. Diuretics and beta-blockers, 
often used for high blood pressure, increase insulin 
resistance and promote the development of diabetes 
in patients treated in this way. Therapy with sacubi-
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tril/valsartan is devoid of these hazards and is likely to 
prevent the development of type 2 diabetes. Patients 
with heart failure and patients with hypertension are 
often treated with the antagonist of mineralocorti-
coid receptor (e.g. spironolactone, eplerenone) and 
the inhibitors of angiotensin convertase. This can 
often lead to dangerous hyperkalaemia. Desai et al. 
compared the incidence of this complication (potas-
sium above 6 mmol/L) in patients treated in this way 
with or without add-on treatment with sacubitril/ 
/valsartan [33]. Hyperkalaemia occurred significantly 
less frequently in patients treated with additional 
sacubitril/valsartan (HR 1.37; p = 0.02).
Some researchers have raised concerns that sacubi-
tril/valsartan inhibits enzymatic degradation of beta 
amyloid, which can lead to accelerated progression of 
Alzheimer’s disease [34]. Although the PARADIGM- 
-HF trial showed no significantly higher prevalence 
of dementia in patients treated with sacubitril/val-
sartan compared to treatment with enalapril (0.36% 
vs 0.29%), further long-term studies are necessary to 
clarify whether this drug may indeed pose a threat 
to patients.
As the above review of the literature shows, sacubi-
tril/valsartan is not only likely to be successfully used 
in patients with heart failure, but it will also enrich 
the arsenal of drugs for hypertension. Sacubitril/val-
sartan is the first drug inhibiting neprilysin and we 
can expect that in the near future there will be more 
drugs from this group that will be even more effective 
in the treatment of hypertension. 
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